March 8 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB PRESENTS LATE-BREAKING DATA FROM PHASE 3 POETYK PSA-2 TRIAL DEMONSTRATING SUPERIORITY OF SOTYKTU (DEUCRAVACITINIB) COMPARED WITH PLACEBO IN ADULTS WITH PSORIATIC ARTHRITIS
BRISTOL-MYERS SQUIBB CO - SOTYKTU WELL-TOLERATED COMPARED TO PLACEBO AND APREMILAST